絞り込み

16603

広告

キンギョの「設計図」解読 (デイリースポーツ)

キンギョのゲノム(全遺伝情報)解読に初めて成功したと、大阪大などのチームが26日付の米科学誌電子版に発表した。ゲノムは生物の設計図ともいわれ、さまざまな形態を持...

  1. 家畜ふん尿:お得に燃料 阪大開発 秋に北...
  2. 科学の森:続く黒潮大蛇行、影響は 12年...
  3. 今どきサイエンス:文化としての科学=鴨志...
  4. 深海アイドル図鑑:/97 宝石サンゴ (...

ニュース一覧

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.

著者 Klok FA , Barco S , Turpie AGG , Haas S , Kreutz R , Mantovani LG , Gebel M , Herpers M , Bugge JP , Kostantinides SV , Ageno W
Br J Haematol.2018 Aug 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (92view , 0users)

Full Text Sources

Venous thromboembolism (VTE)-BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice-based conditions. We calculated the prognostic indices of VTE-BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all-cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at-risk time was 190 days (interquartile range 106-360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3-5·2] and the treatment-adjusted HR was 2·3 (95% CI 1·1-4·5) for VTE-BLEED high (versus low) risk patients: the corresponding values for major bleeding after day 90 were 3·8 (95% CI 1·6-9·3) and 3·2 (95% CI 1·3-7·7), respectively. The predictive value of VTE-BLEED was similar in selected patients with unprovoked VTE or those treated with rivaroxaban. High VTE-BLEED score was associated with higher incidence of all-cause mortality (treatment-adjusted HR 11, 95% CI 4·8-23), but not evidently with recurrent VTE (treatment-adjusted HR 1·5; 95% CI 0·85-2·7). These results confirm the predictive value of VTE-BLEED in practice-based data in patients treated with rivaroxaban or conventional anticoagulation, supporting the hypothesis that VTE-BLEED may be useful for making management decisions on the duration of anticoagulant therapy.
PMID: 30123981 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード